Intermediate-Timed Alemtuzumab May be Associated with Increased Graft Rejection in Reduced-Intensity Bone Marrow Transplant for Sickle Cell Disease
2018
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI